復宏漢霖H藥全國各地首處方快速落地 商業化能力成熟
今日,復宏漢霖自主研發的創新型PD-1抑制劑H藥漢斯狀®治療微衞星高度不穩定 (MSI-H) 實體瘤的首處方由南京金陵醫院腫瘤中心秦叔逵教授等11名知名教授同步開出,標誌着H藥正式進入臨牀應用,為MSI-H實體瘤患者提供免疫治療新選擇。
H藥獲批後,公司全面開啟商業化進程,多方協同、風檣陣馬、快速響應,於獲得上市批件後一週內完成首批發貨。早在去年下半年,公司即圍繞H藥的首個適應症獲批針對其商業渠道和供應鏈等方面展開積極規劃,只為將這款創新好藥快馬急鞭地送達全國患者手中。面對3月的突發疫情,復宏漢霖團隊凝心聚力,在各地以最快速度入庫、上架、開單、配送,一氣呵成,多方保障、共克時艱,將藥品保駕護航送往全國近30個省份100多個城市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.